From the Journals

Can SGLT-2 Inhibitors Shield Against Autoimmune Disease?

Researchers found sodium-glucose cotransporter-2 inhibitors lowered autoimmune rheumatic disease risk by 11% in adults with type 2 diabetes.

Share

5 Key Takeaways

  • 1

    SGLT-2 inhibitors lower autoimmune disease incidence in type 2 diabetes.

  • 2

    Study utilized a cohort of 2,032,157 adults from South Korea.

  • 3

    Hazard ratio for autoimmune diseases was 0.8

  • 4

    Reduction driven by lower risk of inflammatory arthritis.

  • 5

    Increased risk of genital infections noted with SGLT-2 inhibitors.

Original Source(s)

Can SGLT-2 Inhibitors Shield Against Autoimmune Disease?

Researchers found sodium-glucose cotransporter-2 inhibitors lowered autoimmune rheumatic disease risk by 11% in adults with type 2 diabetes.

  • by Kathryn Wighton

  • October 29, 2025

  • 2 min

Related Content

Plozasiran Wins FDA Nod for FCS

Arrowhead’s small interfering RNA therapy reduced triglycerides and lowered pancreatitis risk in the phase 3 PALISADE trial, providing a quarterly self-administered option for patients with familial chylomicronemia syndrome.

Waist Circumference Link to DR

Obesity measure linked to diabetic retinopathy risk in US adults

Testing Metformin’s Reach in PAD

Double-blind trial of 202 patients shows no improvement in 6-minute walk distance at 6 months compared with placebo.